Find similar products:
The text only version may be available in large print, Braille or audio CD.
For further information call emc accessibility on
0800 198 5000.
The product code(s) for this leaflet is: PL 21597/0087.
Sofonac 10 mg/5 mg, 20 mg/10 mg and 40 mg/20 mg prolonged-release tablets
Sofonac 10 mg/5 mg prolonged-release tablets
Sofonac 20 mg/10 mg prolonged-release tablets
Sofonac 30 mg/15 mg prolonged-release tablets
Sofonac 40 mg/20 mg prolonged-release tablets
oxycodone hydrochloride/naloxone hydrochloride
1. What Sofonac is and what it is used for
2. What you need to know before you take Sofonac
3. How to take Sofonac
4. Possible side effects
5. How to store Sofonac
6. Contents of the pack and other information
You have been prescribed Sofonac for the treatment of severe pain, which can be adequately managed only with opioid analgesics.
Sofonac contains oxycodone hydrochloride and naloxone hydrochloride as active substances.
Oxycodone is responsible for the painkilling effect of Sofonac. It is a strong analgesic (“painkiller”) that belongs to a group of medicines called opioids.
Naloxone is intended to bring relief from constipation. Constipation is a typical side effect of treatment with strong painkillers (opioid painkillers).
Talk to your doctor or pharmacist before taking Sofonac
Sleep-related breathing disorders
Sofonac can cause sleep-related breathing disorders such as sleep apnoea (breathing pauses during sleep) and sleep related hypoxemia (low oxygen level in the blood). The symptoms can include breathing pauses during sleep, night awakening due to shortness of breath, difficulties to maintain sleep or excessive drowsiness during the day. If you or another person observe these symptoms, contact your doctor. A dose reduction may be considered by your doctor.
Tolerance, dependence and addiction
This medicine contains oxycodone which is an opioid medicine. Repeated use of opioid painkillers can result in the drug being less effective (you become accustomed to it, known as tolerance). Repeated use of Sofonac may lead to dependence, abuse and addiction which may result in life-threatening overdose. The risk of these side effects can increase with a higher dose and longer duration of use.
Dependence or addiction can make you feel that you are no longer in control of how much medicine you need to take or how often you need to take it. You might feel that you need to carry on taking your medicine, even when it doesn’t help to relieve your pain.
The risk of becoming dependent or addicted varies from person to person. You may have a greater risk of becoming dependent or addicted on Sofonac:
If you notice any of the following signs whilst taking Sofonac, it could be a sign that you have become dependent or addicted.
If you notice any of these signs, speak to your doctor to discuss the best treatment pathway for you, including when it is appropriate to stop and how to stop safely (See section 3, If you stop taking Sofonac).
Tell your doctor if any of the above has ever applied to you in the past. Also, please contact your doctor if you develop any of them while you are taking Sofonac.
Sofonac is not recommended for use in patients with advanced digestive or pelvic cancers where bowel obstruction may be a problem.
If you experience severe diarrhoea at the start of treatment (within the first 3 to 5 days) this may be due to the effect of naloxone. It may be a sign that your bowel movements are returning to normal. If diarrhoea persists after 3 to 5 days, or it gives you cause for concern, please contact your doctor.
If you have been using high doses of another opioid, withdrawal symptoms (such as restlessness, bouts of sweating and muscle pain) may occur when you initially switch to Sofonac. If you experience withdrawal symptoms, you may need to be specially monitored by your doctor.
Do not use Sofonac for acute post-operative pain because of the increased risk of dependency and developing serious breathing problems.
If you are going to have an operation, or have just had an operation, please tell the doctor at the hospital if you are taking Sofonac. Your doctor may adjust your dose.
Contact your doctor if you experience severe upper abdominal pain possibly radiating to the back, nausea, vomiting or fever as this could be symptoms associated with inflammation of the pancreas (pancreatitis) and the biliary tract system.
If you have been taking Sofonac for a long time, you may become tolerant. This means you may need a higher dose to achieve the desired effect. Long-term use of this medicine may also lead to physical dependence. Medicines containing oxycodone should be avoided in patients with a present or past abuse of alcohol, drugs or medicines. Withdrawal symptoms may occur if treatment is stopped too suddenly. If you no longer need treatment, you should reduce your daily dose gradually, in consultation with your doctor.
You may notice remnants of the prolonged-release tablet in your stools. Do not be alarmed, as the active substances will have already been released in the stomach and gut, and absorbed into your body.
Incorrect use of Sofonac
Sofonac must never be abused, particularly if you have a drug addiction. If you are addicted to drugs such as heroin, morphine or methadone, severe withdrawal symptoms are likely if you abuse Sofonac because it contains the active substance naloxone. Pre-existing withdrawal symptoms may be made worse.
You must never misuse Sofonac tablets by dissolving and injecting or inhaling them (e.g. into a blood vessel). They contain talc, which can cause destruction of local tissue (necrosis) and changes in lung tissue (lung granuloma). Misuse can also have other serious consequences which may be fatal.
Sofonac 10mg/5mg, 20 mg/10 mg, 30 mg/15 mg and 40 mg/20 mg
Do not break, chew or crush these tablets so as not to affect the slow release of oxycodone from the tablets. Taking broken, chewed or crushed tablets may result in your body absorbing a potentially fatal dose of oxycodone (see section 3 “If you take more Sofonac than you should”).
The use of Sofonac may produce positive results in doping controls.
The use of Sofonac as a doping agent may become a health hazard.
This medicine should not be given to children or adolescents under 18 years of age as the safety and efficacy have not been shown.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
The risk of side effects is increased if you take Sofonac at the same time as medicines which affect the way the brain works. For example, you may feel very sleepy, or breathing problems (slow and shallow breathing) may get worse.
Examples of medicines that affect the way the brain works include:
The risk of side effects increases, if you use antidepressants (such as citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine). These medicines may interact with oxycodone and you may experience symptoms such as involuntary, rhythmic contractions of muscles, including the muscles that control movement of the eye, agitation, excessive sweating, tremor, exaggeration of reflexes, increased muscle tension, body temperature above 38°C. Contact your doctor when experiencing such symptoms.
Concomitant use of Sofonac and sedative medicines such as benzodiazepines or related medicines increases the risk of drowsiness, difficulties in breathing (respiratory depression), coma and may be life-threatening. Because of this, concomitant use should only be considered when other treatment options are not possible.
However if your doctor does prescribe Sofonac together with sedative medicines the dose and duration of concomitant treatment should be limited by your doctor.
Please tell your doctor about all sedative medicines you are taking, and follow your doctor’s dose recommendation closely. It could be helpful to inform friends or relatives to be aware of the signs and symptoms stated above. Contact your doctor when experiencing such symptoms.
Tell your doctor if you are taking:
Drinking alcohol whilst taking Sofonac may make you feel more sleepy or increase the risk of serious side effects such as shallow breathing with a risk of stopping breathing, and loss of consciousness. It is recommended not to drink alcohol while you are taking Sofonac.
You should avoid drinking grapefruit juice while you are taking Sofonac.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy
Use of Sofonac should be avoided to the extent possible during pregnancy. If used over prolonged periods during pregnancy, oxycodone may lead to withdrawal symptoms in newborn infants. If oxycodone is given during childbirth, respiratory depression (slow and shallow breathing) may occur in the newborn infant.
Breast-feeding
Breast-feeding should be discontinued during treatment with Sofonac. Oxycodone passes into breast milk. It is not known whether naloxone also passes into breast milk. Therefore, a risk for the suckling infant cannot be excluded, in particular following intake of multiple doses of Sofonac.
This medicine can affect your ability to drive or operate machines as it may make you sleepy or dizzy. This is most likely at the start of your treatment, after a dose increase or after switching from a different medicine. These side effects should disappear once you are on a stable dose.
This medicine has been associated with sleepiness and episodes of suddenly falling asleep. If you experience these side effects, you must not drive or operate machines. You should tell your doctor if this occurs.
Talk to your doctor or pharmacist if you are not sure whether it is safe for you to drive while taking this medicine.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Before starting treatment and regularly during treatment, your doctor will discuss with you what you may expect from using Sofonac, when and how long you need to take it, when to contact your doctor, and when you need to stop it (see also if you stop taking Sofonac).
To treat pain
Adults
The usual starting dose is 10 mg oxycodone hydrochloride/5 mg naloxone hydrochloride every 12 hours.
Your doctor will decide how much you should take every day and how to divide your total daily dose into morning and evening doses. Your doctor will also decide on any necessary dose adjustments during treatment depending on your level of pain and individual sensitivity. You should be given the lowest dose needed for pain relief. If you have already been treated with opioids, your treatment with Sofonac may be started at a higher dose.
The maximum daily dose is 160 mg oxycodone hydrochloride and 80 mg naloxone hydrochloride. If you need a higher dose, your doctor may give you additional oxycodone without naloxone. However, the maximum daily dose of oxycodone hydrochloride should not exceed 400 mg. The beneficial effect of naloxone on bowel movements may be affected if additional oxycodone is given without additional naloxone.
If you experience pain between doses, you may need to take an additional fast-acting painkiller.
Sofonac is not suitable for this. Please talk to your doctor.
If you feel that Sofonac is too strong or too weak, please talk to your doctor or pharmacist.
Elderly patients
In general, no dose adjustment is necessary for elderly patients with normal kidney and/or liver function.
Liver or kidney impairment
If you have kidney or mild liver problems, your doctor will prescribe Sofonac with special caution. You must not take Sofonac if you have moderate or severe liver problems (see also section 2. “Do not take Sofonac” and “Warnings and precautions”).
Oral use.
The tablets can be divided into equal doses. Swallow the tablets with a glass of water.
Do not break, chew or crush the tablets.
You can take the tablets with or without food. Take them every 12 hours according to a fixed time schedule. For instance, if you take a tablet at 8 o’clock in the morning, you should take your next tablet at 8 o’clock in the evening.
This medicine is in child-resistant packaging. The tablets have to be pressed firmly out of the blister.
You should not take Sofonac for any longer than you need to. If you have been taking Sofonac for a long time your doctor should regularly check that you still need it.
If you have taken more than the prescribed dose, you must inform your doctor immediately.
An overdose may result in:
In severe cases, loss of consciousness (coma), fluid on the lungs and circulatory collapse may occur, which may be fatal.
You should avoid situations which require you to be alert, e.g. driving.
If you forget to take Sofonac or if you take a lower dose than the one prescribed, you may not feel any effect.
If you forget to take your dose, please follow the instructions below:
Do not take more than one dose within any 8 hour period.
Do not take a double dose to make up for a forgotten dose.
Do not stop taking Sofonac without first speaking with your doctor.
If you do not require any further treatment, your doctor will advise you how to reduce the daily dose gradually. In this way, you will avoid withdrawal symptoms, such as restlessness, bouts of sweating and muscle pain.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Stop taking Sofonac and contact a doctor or go to your nearest emergency department immediately if you experience any of the following symptoms:
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Not known (frequency cannot be estimated from the available data)
Breathing problems, such as breathing more slowly or weakly than expected (respiratory depression), reduction in size of the pupils in the eye, muscle cramps and decreased cough reflex.
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Not known (frequency cannot be estimated from the available data)
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children. Store this medicine in a locked safe and secure storage space, where other people cannot access it. It can cause serious harm and be fatal to people when it has not been prescribed for them.
Do not use this medicine after the expiry date which is stated on the carton and blister after “EXP”. The expiry date refers to the last day of that month.
Do not store above 25°C.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
The active substances are oxycodone hydrochloride and naloxone hydrochloride.
Sofonac 10 mg/5 mg
Each tablet contains 10 mg of oxycodone hydrochloride (equivalent to 9 mg oxycodone) and 5 mg of naloxone hydrochloride (as 5.45 mg naloxone hydrochloride dihydrate, equivalent to 4.5 mg naloxone).
Sofonac 20 mg/10 mg
Each tablet contains 20 mg of oxycodone hydrochloride (equivalent to 18 mg oxycodone) and 10 mg of naloxone hydrochloride (as 10.9 mg naloxone hydrochloride dihydrate, equivalent to 9 mg naloxone).
Sofonac 30 mg/15 mg
Each tablet contains 30 mg of oxycodone hydrochloride (equivalent to 27 mg oxycodone) and 15 mg of naloxone hydrochloride (as 16.35 mg naloxone hydrochloride dihydrate, equivalent to 13.5 mg naloxone).
Sofonac 40 mg/20 mg
Each tablet contains 40 mg of oxycodone hydrochloride (equivalent to 36 mg oxycodone) and 20 mg of naloxone hydrochloride (as 21.8 mg naloxone hydrochloride dihydrate, equivalent to 18 mg naloxone).
The other ingredients are:
Tablet core:
Polyvinyl acetate, Povidone K30, Sodium lauryl sulphate, Silica, colloidal anhydrous, Cellulose, microcrystalline, Magnesium stearate
Tablet coating:
Sofonac 10 mg/5 mg
Polyvinyl alcohol, titanium dioxide (E171), iron oxide red (E172), macrogol 3350, talc.
Sofonac 20 mg/10 mg
Polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc.
Sofonac 30 mg/15 mg
Polyvinyl alcohol, titanium dioxide (E171), iron oxide yellow (E172), macrogol 3350, talc.
Sofonac 40 mg/20 mg
Polyvinyl alcohol, titanium dioxide (E171), iron oxide red (E172), macrogol 3350, talc.
Sofonac 10 mg/5 mg
Pink, oblong, biconvex tablet with break scores on both sides, with a length of 10.2 mm, a width of 4.7 mm and a height of 3.0 - 4.0 mm.
The tablet can be divided into equal doses.
Sofonac 20 mg/10 mg
White, oblong, biconvex tablet with break scores on both sides, with a length of 11.2 mm, a width of 5.2 mm and a height of 3.3 - 4.3 mm.
The tablet can be divided into equal doses.
Sofonac 30 mg/15 mg
Yellow, oblong, biconvex tablet with break scores on both sides, with a length of 12.2 mm, a width of 5.7 mm and a height of 3.3 - 4.3 mm.
The tablet can be divided into equal doses.
Sofonac 40 mg/20 mg
Pink, oblong, biconvex tablet with break scores on both sides, with a length of 14.2 mm, a width of 6.7 mm and a height of 3.6 - 4.6 mm
The tablet can be divided into equal doses.
Child-resistant blisters of 28 and 56 tablets
Bottles with child-resistant closure of 28 and 56 tablets.
Not all pack sizes may be marketed.
This leaflet was last revised in January 2025.